Investigating how a specific enzyme affects cell metabolism and inflammation in acute lung injury.
Official title: Mitochondrial deubiquitinase USP30 regulates cell metabolism-mediated miRNA biogenesis and microvascular inflammation
Funded at Ohio State University · NIH-11048304 · Data updated 2026-11-12
This study is looking at how a specific enzyme called USP30 affects cell health and inflammation in serious conditions like ARDS and sepsis, and it hopes to find new ways to help improve blood vessel function and develop better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | February 1, 2025 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $678,803 |
| NIH project number | 1R01HL171220-01A1 |
| Project ID | NIH-11048304 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients experiencing acute respiratory distress syndrome or sepsis, particularly those caused by bacterial or viral infections.
✕Less likely to help
Patients with chronic inflammatory diseases or those not experiencing acute respiratory distress may not benefit from this research.
What this research studies
This research focuses on understanding the role of the enzyme USP30 in regulating cell metabolism and inflammation, particularly in conditions like acute respiratory distress syndrome (ARDS) and sepsis. The study aims to explore how inhibiting USP30 can improve the function of microvascular endothelial cells, which are crucial for maintaining blood vessel integrity. By examining the molecular pathways involved, including the production of certain microRNAs, the research seeks to identify new therapeutic strategies for treating these life-threatening conditions. Patients may benefit from potential new treatments that target these mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce mortality and improve outcomes for patients suffering from acute inflammatory diseases like ARDS and sepsis.
How similar studies have gone: While the specific approach of targeting USP30 in microvascular inflammation is novel, similar research has shown promise in targeting metabolic pathways for treating acute inflammatory conditions.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Zhao, Yutong — Ohio State University
- Study coordinator: Zhao, Yutong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how trinucleotide repeat expansions cause disease
A research project at Ohio State University is exploring how tiny DNA repeats become unstable and drive neurological and muscular diseases, with potential implications for future therapies.
-
Pediatric Prehospital Airway Resuscitation for Critically Ill Children
This grant tests the best way for paramedics to manage breathing tubes and other airways in seriously ill children before they reach the hospital.
-
From Social Breakups to Brain Changes in Alzheimer’s and Related Dementias
This grant explores how losing social connections may trigger brain changes and inflammation linked to Alzheimer’s disease and related dementias.
-
Understanding why patients with blood cancers start and stick with oral cancer medicines
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
-
How sex and hormones affect alcohol's impact on sleep in adults
This study tests how sex and hormone changes influence how alcohol disrupts sleep in healthy adults, with a focus on women aged 21-45.
-
Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer
A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.